United States President Donald Trump has unveiled a phased tariff roadmap for imported generic medicines, giving pharmaceutical companies a two-year transition period before imposing steep duties designed to encourage domestic manufacturing in the US.
Announcing the decision on his Truth Social platform, Trump said that imported generic medicines will continue to attract zero tariffs from August 1, 2026, for two years.